Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8050)
All Articles published online
|
Publishing Process of This Article
|
Jul 14, 2022 (publication date) through Apr 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bellanti F, Lo Buglio A, Dobrakowski M, Kasperczyk A, Kasperczyk S, Aich P, Singh SP, Serviddio G, Vendemiale G. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol 2022; 28(26): 3243-3257 [PMID: 36051336 DOI: 10.3748/wjg.v28.i26.3243] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i26/3243.htm |
| Number | Citing Articles |
| 1 |
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Yu-Mi Lim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee. Sodium-glucose cotransporter 2 inhibitors ameliorate ER stress-induced pro-inflammatory cytokine expression by inhibiting CD36 in NAFLD progression in vitro. Biochemical and Biophysical Research Communications 2024; 735: 150620 doi: 10.1016/j.bbrc.2024.150620
|
| 2 |
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, Stanisław Surma, Krzysztof J. Filipiak, Aleksandra Gąsecka. The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?. Journal of Cardiovascular Development and Disease 2023; 10(11): 465 doi: 10.3390/jcdd10110465
|
| 3 |
Sara Volpe, Alfredo Vozza, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Alessandro Bergamasco, Domenico Triggiani, Giulia Pierangeli, Giovanni De Pergola, Cosimo Tortorella, Antonio Moschetta, Giuseppina Piazzolla. Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients 2024; 16(22): 3841 doi: 10.3390/nu16223841
|
| 4 |
Jin-Jin Dai, Ya-Fei Zhang, Zhen-Hua Zhang. Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023). World Journal of Gastroenterology 2023; 29(37): 5339-5360 doi: 10.3748/wjg.v29.i37.5339
Abstract(722) |
Core Tip(693) |
Full Article(HTML)(5796)
|
Full Article with Cover (PDF)-23362K(172)
|
Full Article (Word)-2780K(40)
|
Audio-879K(6)
|
Peer-Review Report-223K(93)
|
Answering Reviewers-102K(90)
|
Full Article (PDF)-21753K(299)
|
Full Article (XML)-304K(77)
|
Times Cited (12)
|
Total Visits (11021)
|
Open
|
| 5 |
Yutaro Ogawa, Takashi Nakahara, Yuwa Ando, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masami Yamauchi, Masataka Tsuge, Michio Imamura, Shiro Oka. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes. European Journal of Gastroenterology & Hepatology 2023; 35(9): 989 doi: 10.1097/MEG.0000000000002588
|
| 6 |
Laura A. M. Konings, Lorena Miguelañez‐Matute, Anna M. P. Boeren, Inge A. T. van de Luitgaarden, Femme Dirksmeier, Rob J. de Knegt, Maarten E. Tushuizen, Diederick E. Grobbee, Adriaan G. Holleboom, Manuel Castro Cabezas. Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review. European Journal of Clinical Investigation 2025; 55(4) doi: 10.1111/eci.70003
|
| 7 |
Arianna Maiorana, Francesco Tagliaferri, Carlo Dionisi-Vici. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1145111
|
| 8 |
Rong Xu, Difei Lian, Yan Xie, Zhilei Chen, Yan Wang, Lin Mu, Yuan Wang, Baoyu Zhang. SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review. Frontiers in Bioscience-Landmark 2023; 28(7) doi: 10.31083/j.fbl2807134
|
| 9 |
Agostino Di Ciaula, Leonilde Bonfrate, Jacek Baj, Mohamad Khalil, Gabriella Garruti, Frans Stellaard, Helen H. Wang, David Q.-H. Wang, Piero Portincasa. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. Nutrients 2022; 14(23): 4950 doi: 10.3390/nu14234950
|
| 10 |
Grzegorz Procyk, Jakub Jaworski, Aleksandra Gąsecka, Krzysztof J. Filipiak, Josip A. Borovac. Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors. Advances in Medical Sciences 2024; 69(2): 407 doi: 10.1016/j.advms.2024.09.001
|
| 11 |
Christopher Cunningham, Ahmad Jabri, Laith Alhuneafat, Ashish Aneja. A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors. Current Problems in Cardiology 2023; 48(10): 101817 doi: 10.1016/j.cpcardiol.2023.101817
|
| 12 |
Peipei Zhou, Ying Tan, Zhenning Hao, Weilong Xu, Xiqiao Zhou, Jiangyi Yu. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1144838
|
| 13 |
Xiuying Gao, Chuanming Zhu, Wei Zhu, Lin Wang. Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes. Biomedical Reports 2024; 22(2) doi: 10.3892/br.2024.1904
|
| 14 |
Rahnuma Ahmad, Mainul Haque. Metformin: Beyond Type 2 Diabetes Mellitus. Cureus 2024; doi: 10.7759/cureus.71730
|
| 15 |
Mona Ahmed Amin, Noha Adly Sadik, Hala Ahmed Saad, Mohammed Fawzy, Hend Abdallah Elsheimy. The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease. Internal and Emergency Medicine 2025; doi: 10.1007/s11739-025-03902-w
|
| 16 |
Kosuke Ushiro, Masahiro Matsui, Akira Fukuda, Saori Onishi, Tomohiro Nishikawa, Akira Asai, Soo Ki Kim, Hiroki Nishikawa. Fatty liver index and somatic composition in subjects receiving medical health checkup. Hepatology Research 2025; 55(3): 363 doi: 10.1111/hepr.14127
|
| 17 |
Junpei Hu, Jianhui Teng, Shan Hui, Lihui Liang. SGLT-2 inhibitors as novel treatments of multiple organ fibrosis. Heliyon 2024; 10(8): e29486 doi: 10.1016/j.heliyon.2024.e29486
|
| 18 |
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina 2023; 59(10): 1789 doi: 10.3390/medicina59101789
|
| 19 |
Krishna G. Seshadri, Dakshata Padhye, Surekha Tippisetty, Subhadra Polisetti, Smriti Gadia. Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease—A Real World Retrospective Study from India. International Journal of Clinical Metabolism and Diabetes 2025; 1(1): 11 doi: 10.1177/30502071241281419
|
| 20 |
Ashot A. Avagimyan, Mohammad Sheibani, Artem I. Trofimenko, Evgenii E. Lysov, Farida M. Khamidova, Anahit Z. Aznauryan, Lilit M. Sukiasyan, Karmen T. Sahakyan, Tamara R. Gevorgyan, Marina R. Tatoyan, Gayane L. Mkrtchyan, Goharik L. Meltonyan, Anna R. Petrosyan, Ludmila A. Martemyanova, Ruzanna R. Petrosyan, Olga I. Urazova, Nana V. Pogosova, Nizal Sarrafzadegan. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2). Innovative Medicine of Kuban 2025; 10(1): 101 doi: 10.35401/2541-9897-2025-10-1-101-109
|
| 21 |
Qi Wang, Handan Zhao, Yong Tong, Jiaying Qin, Minghan Zhou, Lijun Xu. Aspartate Aminotransferase/Platelet Ratio Index Upon Admission Predicts 24-Week Mortality in Patients With HIV-Associated Talaromyces marneffei
. Open Forum Infectious Diseases 2023; 10(12) doi: 10.1093/ofid/ofad593
|
| 22 |
K M Prasanna Kumar, A G Unnikrishnan, Pankaj Jariwala, Ashwani Mehta, Richa Chaturvedi, Sagar Panchal, Preet Lakhani, Rachana Acharya, Jitendra Dixit. SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective. Indian Journal of Endocrinology and Metabolism 2024; 28(1): 11 doi: 10.4103/ijem.ijem_377_23
|
| 23 |
Iryna Kostitska, Nadia Protas, Liliia Petrovska. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD). Diabetes Obesity Metabolic Syndrome 2023; (5): 8 doi: 10.57105/2415-7252-2023-5-01
|
| 24 |
Anastasiya M. Kaneva, Evgeny R. Bojko. Fatty liver index (FLI): more than a marker of hepatic steatosis. Journal of Physiology and Biochemistry 2024; 80(1): 11 doi: 10.1007/s13105-023-00991-z
|
| 25 |
Tianfeng Hua, Yuqian Chu, Minjie Wang, Yijun Zhang, Wei Shi, Qihui Huang, Liangliang Zhang, Min Yang. Protective effect of canagliflozin on post-resuscitation myocardial function in a rat model of cardiac arrest. Intensive Care Medicine Experimental 2023; 11(1) doi: 10.1186/s40635-023-00562-y
|
| 26 |
Farah Khaznadar, Ana Petrovic, Omar Khaznadar, Hrvoje Roguljic, Kristina Bojanic, Lucija Kuna Roguljic, Stjepan Siber, Robert Smolic, Ines Bilic-Curcic, George Y. Wu, Martina Smolic. Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy. Journal of Clinical Medicine 2023; 12(20): 6561 doi: 10.3390/jcm12206561
|
| 27 |
Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies. Chinese Journal of Natural Medicines 2024; 22(8): 724 doi: 10.1016/S1875-5364(24)60690-4
|